Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma.
| Condition(s) | Relapsed Refractory Multiple Myeloma (RRMM) |
|---|---|
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to find out how well a combination of two medicines (mezigdomide and elranatamab) works in treating patients with refractory/relapsed multiple myeloma. |
| Who can participate | Inclusion Criteria: * Subjects must satisfy the following criteria to be enrolled in the study: * Subject is ≥ 19 years of age at the time of signing the informed consent form (ICF). ② Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. * Subject is willing and able to adhere to the study visit schedule and other protocol requirements. ④ Subject has documented diagnosis of MM and measurable disease, defined as any of the following: A. M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP) or B. M-protein ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or C. For subjects without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels \> 100 mg/L (10 mg/dL) involved light ch |
| Ages | 19 Years |
| Sex | All |
| Lead sponsor | YOUNGIL KOH |
| Locations | Singapore, Singapore; Singapore, Singapore; Hwasun, South Korea; Seoul, South Korea; Seoul, South Korea; Seoul, South Korea (+1 more sites) |
| Start date | 2024-11-26 |
| NCT ID | NCT06645678 |
| Official listing | https://clinicaltrials.gov/study/NCT06645678 |